NCT00037791View on ClinicalTrials.gov

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 31, 1999

Study Completion Date

September 30, 2002

Conditions
NeoplasmsThrombocytopeniaMultiple MyelomaLymphoma, Malignant
Interventions
DRUG

(PN-152,243)/PN-196,444

Trial Locations (9)

1114

Pfizer Investigational Site, Buenos Aires

1406

Pfizer Investigational Site, Buenos Aires

70115

Pfizer Investigational Site, New Orleans

77030

Pfizer Investigational Site, Houston

90067

Pfizer Investigational Site, Los Angeles

92037

Pfizer Investigational Site, La Jolla

94704

Pfizer Investigational Site, Berkeley

90033-0804

Pfizer Investigational Site, Los Angeles

02990

Pfizer Investigational Site, Mexico City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY